Heather Gibson, PhD profile page

Cancer immunotherapy breakthroughs have shown tremendous promise, but there remains an urgency to determine which patients will respond and why many do not. Dr. Gibson’s lab uses functional genomics and genetically diverse animal models to pinpoint genes and/or pathways involved in immunotherapy resistance. In her research, her team has discovered putative regulators of both immune checkpoint inhibitors and anti-tumor antibody, also known as targeted immunotherapy. The goal is to identify both biomarkers and actionable targets to improve clinical outcomes. Additionally, Dr. Gibson’s team has multiple ongoing collaborative projects aimed at developing new strategies to engage the immune system against cancer.